NCT04029922: Study of MT-5111 in HER2-positive Solid Tumors

NCT04029922
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with current evidence of new or growing CNS metastases during screening – see trial for details
https://ClinicalTrials.gov/show/NCT04029922

Comments are closed.

Up ↑